Abstracts tagged "etanercept"

Abstract Number: 1317 • 2012 ACR/ARHP Annual Meeting
One-Year Results From the Canadian Methotrexate and Etanercept Outcome Study: A Randomized Trial of Etanercept and Methotrexate Versus Etanercept Alone in Rheumatoid Arthritis
Janet E. Pope¹, Boulos Haraoui², J. Carter Thorne³, Melanie Poulin-Costello⁴, Andrew Vieira⁵ and Edward Keystone⁶, ¹Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada, ²Institut de Rhumatologie de Montréal, Montreal, QC, Canada, ³Southlake Regional Health Centre, Newmarket, ON, Canada, ⁴Biostatistics, Amgen Canada Inc., Mississauga, ON, Canada, ⁵Amgen Canada Inc., Mississauga, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada
Background/Purpose: Combination therapy with a biologic and methotrexate (MTX) usually yields better outcomes than biologic monotherapy in rheumatoid arthritis (RA).1,2,3 However, patients may be intolerant…
Abstract Number: 1334 • 2012 ACR/ARHP Annual Meeting
Intra-Articular Etanercept Treatment in Inflammatory Arthritis: A Randomized Double-Blind Placebo-Controlled Trial
Caroline J. Aalbers¹, Danielle M. Gerlag², Koen Vos¹, Gertjan Wolbink³, R. Landewe¹ and Paul P. Tak⁴, ¹Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ²Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁴Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam and GlaxoSmithKline, Amsterdam, Netherlands
Background/Purpose: The use of intra-articular (IA) corticosteroid injections has been widely accepted as a therapy to control local inflammation. Studies on the use of IA…
Abstract Number: 1314 • 2012 ACR/ARHP Annual Meeting
Validation of Algorithms Using Genome-Wide SNP Analysis for Prediction of Remission or Low Disease Activity for Infliximab or Etanercept-Treated RA Patients
Tsukasa Matsubara¹, Satoru Koyano², Keiko Funahashi², James E. Middleton², Takako Miura¹, Kosuke Okuda¹, Takeshi Nakamura¹, Akira Sagawa³, Takeo Sakurai⁴, Hiroaki Matsuno⁵, Tomomaro Izumihara⁶, Eisuke Shono⁷, Kou Katayama⁸, Toyomitsu Tsuchida⁹, Mitsuyoshi Iwahashi¹⁰, Tomomi Tsuru¹¹ and Motohiro Oribe¹², ¹Matsubara Mayflower Hospital, Kato, Japan, ²Research Institute of Joint Diseases, Kobe, Japan, ³Sagawa Akira Rheumatology Clinic, Sapporo, Japan, ⁴Inoue Hospital, Takasaki, Japan, ⁵Matsuno Clinic for Rheumatic Diseases, Toyama, Japan, ⁶Izumihara Rheumatic and Medical Clinic, Kagoshima, Japan, ⁷Shono Rheumatology Clinic, Fukuoka, Japan, ⁸Katayama Orthopedic Rheumatology Clinic, Asahikawa, Japan, ⁹Tsuchida Clinic, Chiba, Japan, ¹⁰Higashi-Hiroshima Memorial Hospital, Higashi-hiroshima, Japan, ¹¹PS Clinic, Fukuoka, Japan, ¹²Oribe Rheumatism and Internal Medicine Clinic, Oita, Japan
Background/Purpose: Achievement of remission or low disease activity with infliximab (IFX) and etanercept (ETN) treatment is currently one of the most important matters in RA…
Abstract Number: 1285 • 2012 ACR/ARHP Annual Meeting
Short-Term Efficacy of Etanercept Plus Methotrexate Vs.Various Disease-Modifying Anti-Rheumatic Combinations with Methotrexate in Established Rheumatoid Arthritis
Roy Fleischmann¹, Andrew S. Koenig², Annette Szumski³, Henk Nab⁴, Lisa Marshall⁵ and Eustratios Bananis³, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²Specialty Care Business Unit, Pfizer Inc., Collegeville, PA, ³Specialty Care, Pfizer Inc., Collegeville, PA, ⁴Pfizer Europe, Rome, Italy, ⁵Pfizer Inc., Collegeville, PA
Background/Purpose: The objective of this study was to assess the short-term benefit of etanercept (ETN) + methotrexate (MTX) vs. various disease-modifying anti-rheumatic drugs (DMARDs; hydroxychloroquine…
Abstract Number: 1286 • 2012 ACR/ARHP Annual Meeting
Antibodies to Etanercept and Adalimumab in Rheumatoid Arthritis Inadequate Responders and Clinical Outcomes After an Active Switch to Infliximab
Chad Pool¹, Gopi Shankar², Allen Schantz², George Gunn², Rebecca Bolce³, Marjatta Leirisalo-Repo⁴, Jim Wang¹, John A. Goldman⁵, Raphael J. DeHoratius⁶, Roy Fleischmann⁷ and Dennis Decktor⁶, ¹Janssen Services, LLC, Horsham, PA, ²Janssen R&D, LLC, PA, ³Crescendo Bioscience Inc., South San Francisco, CA, ⁴Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital, Helsinki, Finland, ⁵Medical Quarters #293, Atlanta, GA, ⁶Medical Affairs, Janssen Services, LLC, Horsham, PA, ⁷Rheumatology, University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: To determine if RA patients (pts) who had an inadequate response to etanercept(ETN) or adalimumab(ADA) and developed antibodies (Abs) to ETN or ADA responded…
Abstract Number: 1275 • 2012 ACR/ARHP Annual Meeting
Fast Remission Response to Etanercept At Week 4 Predicts Better Long-Term Outcomes in Early and Established Rheumatoid Arthritis Compared to Slower Response At Week 12
Bernd Raffeiner¹, Costantino Botsios², Francesca Ometto², Mariagrazia Canova², Livio Bernardi², Cristiana Vezzari², Silvano Todesco², Paolo Sfriso² and Leonardo Punzi², ¹Rheumatology Unit, Department of Medicine - DIMED, University of Padova, Padova, Italy, ²Clinical and Experimental Medicine, Rheumatology Unit - University of Padova, Padova, Italy
Background/Purpose: Achievement of clinical remission not only early in disease course but also early in treatment course may be critical for functional outcome of patients…
Abstract Number: 1165 • 2012 ACR/ARHP Annual Meeting
Factors Associated with Achievement of Inactive Disease in Children with Juvenile Idiopathic Arthritis Treated with Etanercept
Nicoletta Solari¹, Elena Palmisani¹, Alessandro Consolaro¹, Sara Dalprà¹, Benedetta Schiappapietra¹, Giulia Bracciolini¹, Silvia Rosina¹, Giorgia Negro¹, Alberto Martini² and Angelo Ravelli³, ¹Pediatria II, Istituto Giannina Gaslini, Genova, Italy, ²Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH, ³Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: The advent of new therapies for juvenile idiopathic arthritis (JIA), particularly the introduction of biologic medications, has increased considerably the potential for treatment benefit,…
Abstract Number: 2661 • 2012 ACR/ARHP Annual Meeting
Disease Activity Score 28-Joint Count: Are Erythrocyte Sedimentation Rate and C-Reactive Protein Versions Comparable?
Roy Fleischmann¹, Désirée van der Heijde², Andrew S. Koenig³, Ronald Pedersen³, Annette Szumski⁴, Lisa Marshall⁵ and Eustratios Bananis⁴, ¹Southwestern Medical Center at Dallas, University of Texas, Dallas, TX, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Specialty Care, Pfizer Inc, Collegeville, PA, ⁴Specialty Care, Pfizer Inc., Collegeville, PA, ⁵Pfizer Inc., Collegeville, PA
Background/Purpose: Frequently DAS28-CRP is utilized instead of DAS28-ESR to assess rheumatoid arthritis (RA) disease activity; however, values for remission and low disease activity (LDA) for…
Abstract Number: 1174 • 2012 ACR/ARHP Annual Meeting
Severe Adverse Events Associated with Use of Biologic Therapy in Juvenile Idiopathic Arthritis: A Single-Center Study
Ricardo A. G. Russo¹ and Marìa M. Katsicas², ¹Immunology & Rheumatology, Hospital de Pediatria Garrahan, Buenos Aires, Argentina, ²Immunology & Rheumatology., Hospital de Pediatrìa Garrahan, Buenos Aires, Argentina
Background/Purpose: biologic agents have revolutionized the treatment of Juvenile Idiopathic Arthritis (JIA) and other conditions due to their high efficacy and safety. However, with the…
Abstract Number: 2549 • 2012 ACR/ARHP Annual Meeting
Induction of Remission in Patients with up to 12 Months of Moderate-to-Severe Rheumatoid Arthritis Symptoms Treated with Etanercept Plus Methotrexate Over 52 Weeks
Paul Emery¹, Mohammed Hamoudeh², Oliver FitzGerald³, Bernard Combe⁴, Stefanie Gaylord⁵, Theresa Williams⁵, Jack Bukowski⁶, Ronald Pedersen⁵, Andrew S. Koenig⁷ and Bonnie Vlahos⁵, ¹Department of Rheumatology, Leeds General Infirmary, Leeds, United Kingdom, ²Department of Medicine - Rheumatology, Hamad Medical Corporation, Doha, Qatar, ³Department of Rheumatology, St.Vincent's University Hospital, Dublin, Ireland, ⁴Department of Rheumatology, Lapeyronie Hospital, Montpellier, France, ⁵Department of Specialty Care, Pfizer Inc., Collegeville, PA, ⁶Department of Specialty Care, Pfizer Inc, Collegeville, PA, ⁷Pfizer, Inc., Collegeville, PA
Background/Purpose: In the COMET study, etanercept (ETN) plus methotrexate (MTX) therapy in patients with early rheumatoid arthritis (RA) yielded high clinical remission rates,1 but whether…
Abstract Number: 1147 • 2012 ACR/ARHP Annual Meeting
Definition of Improvement Thresholds in Juvenile Idiopathic Arthritis Using the JADAS
Gerd Horneff¹ and Ingrid Kaul², ¹Department of Pediatrics, Centre of Pediatric Rheumatology, Sankt Augustin, Germany, ²Institute of Medical Statistics, Informatics and Epidemiology, University of Cologne, Cologne, Germany
Definition of improvement thresholds in juvenile idiopathic arthritis (JIA) using the JADAS Background/Purpose: Evaluation of disease activity in JIA is fundamental in clinical assessment. The…
Abstract Number: 2465 • 2012 ACR/ARHP Annual Meeting
Seroresponse Rates After Influenza Vaccination in Rheumatoid Arthritis Patients Treated with Biological Agents During the 2011–2012 Flu Season
Masatoshi Hayashi¹, Toshihisa Kojima², Naoki Ishiguro³, Tomonori Kobayakawa⁴ and Toshihisa Kanamono¹, ¹Departments of Orthopedic surgery and Rheumatology, Nagano Red Cross Hospital, Nagano, Japan, ²Orthopedic Surgery and Rheumatology, Nagoya Univeristy, School of Medicine, Nagoya, Japan, ³Department of Orthopedic Surgery, Nagoya University, Graduate School & Faculty of Medicine, Nagoya, Aichi, Japan, ⁴Orthopedic Surgery, Nagoya university, Nagoya, Japan
Background/Purpose: At present, annual vaccination against influenza is recommended for rheumatoid arthritis (RA) patients. However, whether humoral responses to influenza vaccine are impaired in RA…
Abstract Number: 1004 • 2012 ACR/ARHP Annual Meeting
A Unique Single Nucleotide Polymorphism in the 3’ UTR of the MED29 Gene On Chromosome 19 Is Associated with the Clinical Outcome of Different Biologic Response Modifiers
Susanne Drynda¹, David Leesch², Marietta Gloetzner² and Joern Kekow², ¹Clinic of Rheumatology, Univ of Magdeburg, Clinic of Rheumatology, Vogelsang-Gommern, Germany, ²Clinic of Rheumatology, Univ of Magdeburg, Vogelsang-Gommern, Germany
Background/Purpose: Due to the wide range of highly specific and effective biologic response modifiers that are available today for the treatment of RA it has…
Abstract Number: 2227 • 2012 ACR/ARHP Annual Meeting
Low Dosage with Escalating Dosage of Infliximab in Psoriatic Arthritis Gives the Same Treatment Results as Standard Dosage of Adalimumab or Etanercept: Results From the Nationwide Registry ICEBIO
Bjorn Gudbjornsson¹ and Niels Steen Krogh², ¹Department of Rheumatology, Center for Rheumatology Research (ICEBIO), Landspitali – The National University Hospital of Iceland, Reykjavik, Iceland, ²ZiteLab ApS, Copenhagen, Denmark
Background/Purpose: To explore differences in response to low dosage (2.3mg/kg) regimen of infliximab with possible escalating dosage in comparison to standard dosage of etanercept and…
Abstract Number: 475 • 2012 ACR/ARHP Annual Meeting
Immunologic Responsiveness in Patients with Juvenile Idiopathic Arthritis On Methotrexate and Etanercept: 23 Valent Pneumococcal Vaccination
Ankur A. Kamdar¹, Patricia C. Giclas² and Barry L. Myones³, ¹Rheumatology, University of Texas Medical School at Houston, Houston, TX, ²Pediatric Allergy and Immunology, National Jewish Health, Denver, CO, ³Pediatrics, Baylor College of Medicine, Houston, TX
Background/Purpose: There is a paucity of data regarding response to vaccinations in patients with juvenile idiopathic arthritis (JIA) treated with methotrexate (MTX). It is also…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].